Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
NR

NASDAQ · NRIX

Nurix Therapeutics, Inc.

Healthcare · Biotechnology

$25.81

Down-$0.45 (-1.71%)

Updated Sep 11, 2026, 3:05 AM

SID Score

6.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.47B
P/E ratio
-6.56
Dividend yield
0.00%
52-week range
$8.20 – $28.23
Volume
1.03M
Avg. volume
1.68M

Price performance

NRIX price history

1M range · 20 trading sessions · Daily adjusted prices

NRIX closed at $25.81 after 20 trading sessions, down 5.08% for the selected period.

Last close
$25.81
Period change
-5.08%
Period low
$25.32
Period high
$27.79
Daily close
View OHLC price history
NRIX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$25.89$25.99$25.50$25.811.03M
Sep 9, 2026$26.46$26.695$25.91$26.261.03M
Sep 8, 2026$25.42$26.42$25.36$26.131.29M
Sep 4, 2026$25.19$26.22$24.97$26.141.23M
Sep 3, 2026$25.82$26.16$24.95$25.321.38M
Sep 2, 2026$26.35$26.915$25.39$25.821.74M
Sep 1, 2026$25.47$26.11$25.47$26.041.6M
Aug 31, 2026$26.00$26.23$25.17$25.781.24M
Aug 28, 2026$26.52$26.87$26.125$26.21929.23K
Aug 27, 2026$26.795$27.50$26.235$26.8751.26M
Aug 26, 2026$26.77$27.23$26.44$26.71551.88K
Aug 25, 2026$26.72$27.38$26.378$26.951.18M
Aug 24, 2026$26.37$26.685$25.86$26.27874.21K
Aug 21, 2026$27.41$27.50$26.70$26.721.49M
Aug 20, 2026$27.33$27.565$26.6792$27.051.09M
Aug 19, 2026$27.50$28.23$27.015$27.792.1M
Aug 18, 2026$26.51$27.04$26.51$26.93816.02K
Aug 17, 2026$26.62$27.22$26.50$27.171.15M
Aug 14, 2026$27.01$27.245$26.19$27.05738.5K
Aug 13, 2026$26.92$27.35$26.44$27.191.37M

Latest NRIX news

The latest Smart Investors Daily articles mentioning NRIX.

Stock researchCompany · Overview

NRIX research

Overview

Company profile and research snapshot.

Company profile

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$27.78
Implied upside
—
Analysts
—
NRIX recent ratings
DateFirmRatingTarget
Aug 10, 2026RBC CapitalOutperform—
Aug 4, 2026NeedhamBuy—
Jul 28, 2026Morgan StanleyOverweight—
Jul 22, 2026UBSBuy—
Jul 13, 2026MizuhoOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 1, 2026

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Company management will participate in fireside chats at the following investor conferences: Wells Fargo Healthcare ConferenceTuesday, September 8, 2026, at 3:00 p.m. ETH.C. Wainwright Healthcare ConferenceMonday, September 14, 2026, at 1:

Yahoo · Aug 5, 2026

Nurix Therapeutics (NRIX) Lands $10 Million Milestone As Phase 3 Trial Begins

Nurix Therapeutics (NasdaqGM:NRIX) announced a $10 million milestone payment tied to the first in human trial of an oral STAT6 degrader in its collaboration with Sanofi. The company also reported enrollment of the first patient in a pivotal global Phase 3 trial of bexobrutideg for relapsed or refractory chronic lymphocytic leukemia in partnership with Roche. Both programs advance Nurix's clinical pipeline in targeted protein degradation and expand its work with large pharmaceutical...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By